. 2018 Jan 19;22(3):1650–1665. doi: 10.1111/jcmm.13442

Table 5.

Correlations between the protein expressions of GP73, TGF‐β1 and Smad2 with clinicopathological characteristics of patients with bladder cancer

Characteristic	n	GP73		Positive rates (%)	P	TGF‐β1		Positive rates (%)	P	Smad2		Positive rates (%)	P
Characteristic	n	+	−	Positive rates (%)	P	+	−	Positive rates (%)	P	+	−	Positive rates (%)	P
Age (year)
<65	49	30	19	61.22	0.914	34	15	69.39	0.491	30	19	61.22	0.361
≥ 65	53	33	20	62.26	0.914	40	13	75.47	0.491	37	16	69.81	0.361
Gender
Male	54	34	20	62.96	0.792	38	16	70.37	0.601	34	20	62.96	0.539
Female	48	29	19	60.42	0.792	36	12	75.00	0.601	33	15	68.75	0.539
Pathologic stage
LMP	17	5	12	29.41	<0.001	9	8	52.94	0.009	8	9	47.06	0.010
LG	35	19	16	54.29		22	13	62.86		19	16	54.29
HG	50	39	11	78.00		43	7	86.00		40	10	80.00
MIBC
Yes	52	26	26	50.00	0.013	31	21	59.62	0.003	28	24	53.85	0.010
No	50	37	13	74.00	0.013	43	7	86.00	0.003	39	11	78.00	0.010
TNM stage
I–II stage	65	28	37	43.08	0.013	42	23	64.62	0.003	38	27	58.46	0.010
III–IV stage	37	35	2	94.59	0.013	32	5	86.49	0.003	29	8	78.38	0.010
LNM
Yes	35	32	3	91.43	<0.001	31	4	88.57	0.009	28	7	80.00	0.028
No	67	31	36	46.27	<0.001	43	24	64.18	0.009	39	28	58.21	0.028

GP73, Golgi membrane protein 73; TGF‐β1, transforming growth factor‐β1; LMP, low malignant potential; LG, low grade; HG, high grade; MIBC, muscle‐invasive bladder cancer; TNM, tumour node metastasis; LNM, lymph node metastasis.